| Code | CSB-RA875653MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to PTH-0300, targeting interleukin-25 (IL-25), also known as IL-17E. IL-25 is a member of the IL-17 cytokine family that plays a crucial role in type 2 immune responses by promoting the production of Th2-associated cytokines including IL-4, IL-5, and IL-13. This cytokine is primarily produced by epithelial cells, innate lymphoid cells, and certain immune cell populations in response to allergens, parasites, and tissue damage. IL-25 has been implicated in the pathogenesis of allergic diseases such as asthma, atopic dermatitis, and allergic rhinitis, as well as in inflammatory bowel disease and certain fibrotic conditions.
PTH-0300 represents a therapeutic antibody candidate designed to neutralize IL-25 activity, making this biosimilar a valuable tool for investigating type 2 inflammation and allergic disease mechanisms. This antibody enables researchers to explore IL-25-mediated signaling pathways, evaluate its role in various disease models, and study potential therapeutic interventions targeting type 2 immune responses in preclinical settings.
There are currently no reviews for this product.